Status:
COMPLETED
Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic
Lead Sponsor:
Institut Bergonié
Conditions:
Sars-CoV2
Serum; Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an imp...
Eligibility Criteria
Inclusion
- Adult 18 years-old and older.
- Person in employment (on fixed-term or permanent contracts) since (at least) March 17th, 2020, the date of national implementation of containment measures in response to the COVID-19 pandemic.
- Signed informed consent.
- Person affiliated to a French social security regimen in accordance with Article 1121-11 of the French Public Health Code).
Exclusion
- Report of known active SARS-CoV-2 infection within 10 days prior to the date of signing the consent. Known active SARS-CoV-2 infection is defined as a positive result on a diagnostic RT-PCR test.
- Presence of known symptoms suggestive of COVID-19 within 10 days prior to the date of signing consent: fever, fatigue, dry cough, shortness of breath, loss of taste and/or smell, headache, body aches, aches and pains, conjunctivitis or colds, digestive disorders (vomiting, diarrhea).
- A person who is unable to follow and comply with research procedures due to geographical, social or psychological reasons.
- Pregnant or breastfeeding woman.
- Person deprived of their liberty, incapable or incapable of giving their consent.
Key Trial Info
Start Date :
June 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 4 2021
Estimated Enrollment :
526 Patients enrolled
Trial Details
Trial ID
NCT04426006
Start Date
June 18 2020
End Date
October 4 2021
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Bergonié
Bordeaux, France, 33076